A Phase II Study of Busulfan & Melphalan as Conditioning Regimen for ASCT in Patients Who Received Bortezomib Based Induction for Newly Diagnosed Multiple Myeloma Followed by Lenalidomide Maintenance Until Progression
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 18 Apr 2019
Price : $35 *
At a glance
- Drugs Busulfan (Primary) ; Lenalidomide (Primary) ; Melphalan (Primary) ; Autologous stem cell therapy
- Indications Multiple myeloma
- Focus Therapeutic Use
- Acronyms BuMelMCRN001
- 05 Mar 2018 Planned primary completion date changed from 1 Dec 2017 to 1 Jul 2022.
- 20 Sep 2017 Planned End Date changed from 1 Jul 2022 to 1 Dec 2022.
- 20 Sep 2017 Planned primary completion date changed from 1 Apr 2017 to 1 Dec 2017.